Type 2 Diabetes Trial, Recruiting NCT07457580 Sponsor: Sanofi Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07457580
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A signed consent form (or assent form for those under 18 years old) must be completed before any study activities take place, in line with local rules — or an approved waiver of this requirement must be in place.
  • People who received at least 1 day of teplizumab treatment through a Managed Access Program (MAP) (confirm with trial site).

Who may not be able to join:

  • People who were already taking part in another interventional clinical trial on the date they started this study — meaning they were already receiving an experimental treatment or procedure being tested in a separate study that required following a specific research protocol rather than standard medical care.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
16 March 2026
Est. completion
30 November 2026

Where this trial is recruiting

🇧🇪 Belgium 🇫🇷 France 🇮🇹 Italy 🇪🇸 Spain 🇬🇧 United Kingdom

Primary endpoints

Participant demographics at teplizumab initiation; Participants' family history of T1D and autoimmune diseases; Presence of T1D susceptibility genes; Presence of T1D susceptibility genes; Participants' medical history

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov